HilleVax, Inc. (NASDAQ:HLVX) Sees Large Decrease in Short Interest

HilleVax, Inc. (NASDAQ:HLVX) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,180,000 shares, a decline of 6.3% from the October 15th total of 1,260,000 shares. Currently, 6.4% of the shares of the company are short sold. Based on an average daily trading volume, of 259,400 shares, the short-interest ratio is presently 4.5 days.

HilleVax Price Performance

HilleVax stock traded up $0.01 during midday trading on Monday, hitting $1.84. The company’s stock had a trading volume of 9,575 shares, compared to its average volume of 432,082. The company has a market cap of $91.40 million, a price-to-earnings ratio of -0.59 and a beta of 0.78. HilleVax has a 1-year low of $1.55 and a 1-year high of $20.22. The company has a 50-day moving average price of $1.82 and a two-hundred day moving average price of $5.77.

HilleVax (NASDAQ:HLVX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.10). Sell-side analysts forecast that HilleVax will post -2.64 EPS for the current year.

Institutional Investors Weigh In On HilleVax

Several institutional investors and hedge funds have recently bought and sold shares of HLVX. Barclays PLC lifted its holdings in shares of HilleVax by 255.6% during the 3rd quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after acquiring an additional 30,213 shares during the period. Zacks Investment Management boosted its holdings in shares of HilleVax by 411.9% in the 3rd quarter. Zacks Investment Management now owns 92,803 shares of the company’s stock valued at $163,000 after purchasing an additional 74,673 shares in the last quarter. Jane Street Group LLC increased its stake in shares of HilleVax by 81.7% in the 3rd quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock valued at $139,000 after purchasing an additional 35,546 shares during the last quarter. Braidwell LP bought a new stake in shares of HilleVax during the 3rd quarter worth $1,873,000. Finally, Verition Fund Management LLC acquired a new stake in HilleVax in the third quarter valued at about $331,000. Institutional investors own 86.42% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating and set a $2.00 price objective on shares of HilleVax in a report on Monday, August 12th. Six analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $3.00.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.